PPH - ETF AI Analysis
Top Page
VanEck Pharmaceutical ETF (PPH)
Rating:73Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown steady gains over the past month, three months, and year to date, indicating solid recent momentum.
Leading Pharmaceutical Holdings
Several of the largest positions, including major drug makers like Eli Lilly, Merck, Bristol-Myers Squibb, AbbVie, and Johnson & Johnson, have delivered strong year-to-date performance that supports the fund’s returns.
Focused Healthcare Exposure
By concentrating on the health care sector, the ETF gives investors targeted exposure to large, established pharmaceutical companies that can benefit from long-term demand for medicines.
Negative Factors
High Stock Concentration
A small number of companies, especially Eli Lilly and a few other large positions, make up a big share of the portfolio, increasing the impact if any of these stocks stumble.
Sector Concentration Risk
Almost all assets are in the health care sector, so the fund could be hit hard if pharmaceutical stocks face regulatory, pricing, or industry-specific challenges.
Mixed Performance Among Top Holdings
Some key positions like Novo Nordisk and Pfizer have shown weak or slightly negative year-to-date performance, which can drag on overall returns if this trend continues.
PPH vs. SPDR S&P 500 ETF (SPY)
AUM994.73M
RegionGlobal
Expense Ratio0.36%
Beta0.33
IssuerVanEck
Inception DateDec 20, 2011
Dividend Yield1.99%
Asset ClassEquity
Index TrackedMVIS US Listed Pharmaceutical 25
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume195,152
30 Day Avg. Volume265,837
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
130.94Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering25
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PPH Summary
VanEck Pharmaceutical ETF (PPH) is a fund that follows the MVIS US Listed Pharmaceutical 25 Index, focusing on major drug and medicine makers. It holds big, well-known companies like Eli Lilly and Pfizer, along with other global pharmaceutical leaders. Investors might consider PPH if they want simple, one-stop exposure to the healthcare and drug industry, which can benefit from aging populations and rising demand for treatments. However, this ETF is heavily concentrated in pharmaceutical stocks, so its price can swing with changes in drug regulation, patent issues, and overall health care market conditions.
How much will it cost me?The VanEck Pharmaceutical ETF (PPH) has an expense ratio of 0.36%, which means you’ll pay $3.60 per year for every $1,000 invested. This is slightly higher than the average for passively managed ETFs because it focuses on a specialized sector, the pharmaceutical industry, which may require more research and management to track effectively.
What would affect this ETF?The VanEck Pharmaceutical ETF (PPH) could benefit from trends like aging populations, increased healthcare spending, and advancements in medical research, which drive demand for innovative treatments and medications. However, it may face challenges from regulatory changes, patent expirations, or pricing pressures in the pharmaceutical industry, which could impact the profitability of its top holdings like Eli Lilly, Novartis, and Pfizer.
PPH Top 10 Holdings
PPH is essentially a bet on Big Pharma, with Eli Lilly sitting in the driver’s seat: its longer-term gains help power the fund, even though the stock has cooled recently. Merck, Bristol-Myers Squibb, AbbVie, and Johnson & Johnson form a strong supporting cast, all showing rising momentum that keeps the ETF’s health in good shape. Novo Nordisk is more of a mixed story, losing steam this year and acting as a small drag. With all holdings in global drugmakers, the fund is tightly focused on the pharmaceutical world rather than broader health care.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 18.96% | $188.38M | $1.05T | 47.70% | 72 Outperform | |
| Merck & Company | 11.10% | $110.26M | $355.10B | 73.81% | 80 Outperform | |
| Novartis | 9.33% | $92.70M | $250.94B | 10.50% | 80 Outperform | |
| Pfizer | 5.18% | $51.47M | $157.99B | 16.13% | 74 Outperform | |
| Bristol-Myers Squibb | 4.95% | $49.17M | $130.00B | 37.75% | 78 Outperform | |
| Novo Nordisk | 4.93% | $48.99M | $189.94B | -21.50% | 73 Outperform | |
| McKesson | 4.81% | $47.79M | $102.78B | 23.91% | 62 Neutral | |
| AbbVie | 4.64% | $46.10M | $454.36B | 17.76% | 66 Neutral | |
| Johnson & Johnson | 4.57% | $45.42M | $640.02B | 49.15% | 78 Outperform | |
| GlaxoSmithKline | 4.06% | $40.33M | $95.90B | 17.88% | 77 Outperform |
PPH Technical Analysis
Positive
―
Price Trends
111.64
Negative
107.39
Positive
105.45
Positive
Market Momentum
-0.31
Positive
46.06
Neutral
10.09
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PPH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 113.75, equal to the 50-day MA of 111.64, and equal to the 200-day MA of 105.45, indicating a neutral trend. The MACD of -0.31 indicates Positive momentum. The RSI at 46.06 is Neutral, neither overbought nor oversold. The STOCH value of 10.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PPH.
PPH Peer Comparison
Comparison Results
Performance Comparison
PPH
VanEck Pharmaceutical ETF
109.44
23.02
26.64%
SLVP
iShares MSCI Global Silver Miners ETF
―
―
―
GII
SPDR S&P Global Infrastructure ETF
―
―
―
AVRE
Avantis Real Estate ETF
―
―
―
BBH
VanEck Biotech ETF
―
―
―
CANC
Tema Oncology ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents